At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Pramipexole Dihydrochloride +1 moredrug
Likely dose
Pramipexole Dihydrochloride 0.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Relative Bioavailability Study of 0.25 mg Pramipexole Dihydrochloride Tablets Under Non-Fasting Conditions
In Brief
A Phase 1 clinical trial evaluating Pramipexole Dihydrochloride for Healthy. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The object of this study was to compare the relative bioavailability (rate and extent of absorption) of Pramipexole Dihydrochloride Tablets 0.25 mg by Barr Laboratories, Inc. with that of Mirapex® Tablets 0.25 mg distributed by Boehringer Ingelheim Pharmaceuticals, Inc. following a single oral dose in healthy adults under non-fasting conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2005
Primary CompletionMar 2005
First PostedFeb 2010
TodayJul 2026
First PostedFeb 24, 2010
Enrollment StartFeb 1, 2005
Primary CompletionMar 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.4 years ago
Interventions
Pramipexole Dihydrochloridedrug
0.25 mg Tablet
Pramipexole Dihydrochloridedrug
0.25 mg Tablet